EA202191764A1 - SUBSTITUTED OXOPYRIDINE DERIVATIVES - Google Patents

SUBSTITUTED OXOPYRIDINE DERIVATIVES

Info

Publication number
EA202191764A1
EA202191764A1 EA202191764A EA202191764A EA202191764A1 EA 202191764 A1 EA202191764 A1 EA 202191764A1 EA 202191764 A EA202191764 A EA 202191764A EA 202191764 A EA202191764 A EA 202191764A EA 202191764 A1 EA202191764 A1 EA 202191764A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
preparation
Prior art date
Application number
EA202191764A
Other languages
Russian (ru)
Inventor
Зузанне Рёхриг
Зебастиан Эссиг
Паскаль Эллерброкк
Зоня Анлауф
Томас Неубауэр
Александер Хиллиш
Катарина Майер
Штефан Найтмайер
Адриан Терстееген
Мартина Шефер
Ян Штампфусс
Дитер Ланг
Хонгпинг Ванг
Цзэнцян Цзоу
Сянхай Мэн
Керстен Маттиас Герике
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of EA202191764A1 publication Critical patent/EA202191764A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к замещенным оксопиридиновым производным и способам их получения, а также к их применению для получения лекарственных средств для лечения и/или профилактики заболеваний, в частности сосудистых нарушений, предпочтительно тромботических или тромбоэмболических нарушений, и/или тромботических или тромбоэмболических осложнений.The invention relates to substituted oxopyridine derivatives and methods for their preparation, as well as their use for the preparation of drugs for the treatment and/or prevention of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders, and/or thrombotic or thromboembolic complications.

EA202191764A 2018-12-21 2019-12-18 SUBSTITUTED OXOPYRIDINE DERIVATIVES EA202191764A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
EA202191764A1 true EA202191764A1 (en) 2021-10-22

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191764A EA202191764A1 (en) 2018-12-21 2019-12-18 SUBSTITUTED OXOPYRIDINE DERIVATIVES

Country Status (22)

Country Link
EP (1) EP3898633A1 (en)
JP (1) JP2022514303A (en)
KR (1) KR20210106504A (en)
CN (1) CN113474348A (en)
AR (1) AR117435A1 (en)
AU (1) AU2019407909B2 (en)
BR (1) BR112021009435A2 (en)
CA (1) CA3124220A1 (en)
CL (1) CL2021001613A1 (en)
CO (1) CO2021007908A2 (en)
CR (1) CR20210342A (en)
DO (1) DOP2021000128A (en)
EA (1) EA202191764A1 (en)
EC (1) ECSP21043895A (en)
IL (1) IL283990A (en)
JO (1) JOP20210161A1 (en)
MA (1) MA54521A (en)
MX (1) MX2021007508A (en)
PE (1) PE20211790A1 (en)
SG (1) SG11202104384PA (en)
TW (1) TW202039510A (en)
WO (1) WO2020127504A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019236369B2 (en) * 2018-03-15 2024-04-18 Bayer Aktiengesellschaft Preparative process of two 4-{[(2S)-2-{4-[5-chloro-2-(1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
CN114105881B (en) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 Platelet aggregation inhibitor, and preparation method and application thereof
AU2022235150A1 (en) 2021-03-09 2023-08-31 Bayer Aktiengesellschaft Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide
IL305235A (en) 2021-03-09 2023-10-01 Bayer Ag Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (en) * 2022-02-25 2022-05-31 滁州学院 Preparation method of alkyl alcohol
CN116874469B (en) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 Oxo-pyridine compound, intermediate, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (en) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituted indazoles
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (en) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
CA2918814C (en) 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
JP6368367B2 (en) 2013-10-30 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト Substituted oxopyridine derivatives
WO2016046159A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2712886T3 (en) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa
US10071995B2 (en) 2014-09-24 2018-09-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197896B1 (en) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046166A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2713624T3 (en) 2014-09-24 2019-05-23 Bayer Pharma AG Substituted oxopyridine derivatives
US20190119213A1 (en) 2015-03-19 2019-04-25 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
WO2017037051A1 (en) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
PE20211790A1 (en) 2021-09-09
JP2022514303A (en) 2022-02-10
AU2019407909A1 (en) 2021-05-27
KR20210106504A (en) 2021-08-30
SG11202104384PA (en) 2021-05-28
CO2021007908A2 (en) 2021-07-19
CN113474348A (en) 2021-10-01
TW202039510A (en) 2020-11-01
ECSP21043895A (en) 2021-07-30
CA3124220A1 (en) 2020-06-25
AU2019407909B2 (en) 2023-05-25
EP3898633A1 (en) 2021-10-27
BR112021009435A2 (en) 2021-08-17
AR117435A1 (en) 2021-08-04
JOP20210161A1 (en) 2023-01-30
DOP2021000128A (en) 2021-09-30
MX2021007508A (en) 2021-08-05
MA54521A (en) 2022-03-30
CL2021001613A1 (en) 2021-12-03
WO2020127504A1 (en) 2020-06-25
IL283990A (en) 2021-07-29
CR20210342A (en) 2021-08-09

Similar Documents

Publication Publication Date Title
EA202191764A1 (en) SUBSTITUTED OXOPYRIDINE DERIVATIVES
EA201890111A1 (en) SUBSTITUTED OXOPYRIDINE DERIVATIVES
EA202092779A1 (en) SUBSTITUTED DIHYDROPYRAZOLOPYRAZINE CARBOXAMIDE DERIVATIVES
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA202091709A1 (en) DNA PC INHIBITORS
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
EA201791507A1 (en) PYRROLO- AND PYRAZOLOPYRIMIDINES AS UBIKVITIN-SPECIFIC PROTEASE INHIBITORS 7
EA201792354A1 (en) BATCHOLEIC ACID COMPOSITIONS AND METHODS OF APPLICATION
EA201791168A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR EYE DISEASES
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA202091708A1 (en) DNA PC INHIBITORS
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
EA201600288A1 (en) SUBSTITUTED PHYLALANINE DERIVATIVES
EA202191122A1 (en) SELECTIVE TO RGMc INHIBITORS AND THEIR APPLICATION
CY1124492T1 (en) 7-Substituted 1-aryl-naphthyridine-3-carboxamides and their use
EA201792341A1 (en) DERIVATIVES OF PYRAZOLA SUITABLE AS INHIBITOR PROTEINS ACTIVATING 5-LIPOXYGENASE (FLAP)
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
EA202091655A1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF RETINAL DISORDERS
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
EA202191115A1 (en) NEW PYRIDAZINES
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
EA201992389A1 (en) SUBSTITUTED N-ARILETHYL-2-AMINOCHINOLIN-4-CARBOXAMIDES AND THEIR APPLICATION
EA202092045A1 (en) TREATMENT AND PREVENTION OF PREECLAMPSIA
EA201692051A1 (en) ARYL SUBSTITUTED HETEROCYCLILESULPHONES